
    
      Inclusion Criteria:

        1. All patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man
           or woman aged from 15 to 70 years old, SLEDAI≥8;

        2. Lupus nephritis with 24h urine protein≥1g;

        3. Refractory disease as determined by failure of the following regimens:

           Trial of corticosteroids (oral prednisone more than 20 mg/day); Trial of
           cyclophosphamide 0.4 ~ 0.6 / m2 every two weeks for six months, or other
           immunosuppressive drugs, such as mycophenolate mofetil 2 g / day, for three months;

        4. Patients must sign an informed consent indicating that they are aware of the
           investigational nature of the study in keeping with the policy of the hospital;

        5. Willing to use contraception throughout the study and for 12 months following treatment
    
  